Screening for neuroblastoma is ineffective in reducing the incidence of unfavourable advanced stage disease in older children

European Journal of Cancer

Volumn 33, Issue 12, 1997, Pages 2106-2112

  Woods, W G ^a   Tuchman, M ^a   Robison, L L ^a   Bernstein, M ^b   Leclerc, J M ^c   Brisson, L C ^d   Brossard, J ^e   Hill, G ^f   Shuster, J ^g   Luepker, R ^a   Byrne, T ^a   Weitzman, S ^h   Bunin, G ⁱ   Lemieux, B ^e   Brodeur, G M ⁱ  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^f Bureau of Chronic Epidemiology   (Canada)

^g University of Florida ^*  (United States)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cancer screening; Childhood cancer; Neuroblastoma; Newborn screening; Population studies

Indexed keywords

CANCER SCREENING; CANCER STAGING; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL;

CANADA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MASS SCREENING; NEOPLASM STAGING; NEUROBLASTOMA; PATIENT COMPLIANCE;

EID: 0031408772     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00310-9     Document Type: Conference Paper

References (55)

1. Woods W. G., Tuchman M., Robison L. L., et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet. 348:1996;1682-1687.
2. Young JL, Ries LG, Silverberg E, et al. Cancer incidence, survival and mortality in children under 15 years of age. Cancer 1986, 58, 598-602.
3. Bernstein ML, Leclerc JM, Bunin G, et al. A population-based study of neuroblastoma incidence, survival and mortality in North America. J Clin Oncol 1992, 10, 323-329.
4. Rosen EM, Cassady JR, Frantz CN, et al. Neuroblastoma: the Joint Center for Radiation Therapy/Dana Farber Cancer Institute/Children's Hospital experience. J Clin Oncol 1984, 2, 719-732.
5. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991, 9, 581-591.
6. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastoma. N Engl J Med 1985, 313, 1111-1116.
7. Sawada T, Todo S, Fujita K, et al. Mass screening of neuroblastoma in infancy. Am J Dis Child 1982, 136, 710-712.
8. Sawada T, Nakata T, Takasugi N, et al. Mass screening for neuroblastoma in infants in Japan. Lancet 1984, 2, 271-273.
9. Sawada T, Kidowaki T, Sakamoto I, et al. Neuroblastoma: mass screening for early detection and its prognosis. Cancer 1984, 53, 2731-2735.
10. Nishi M, Miyake H, Takeda T, et al. Effects of the mass screening of neuroblastoma in Sapporo City. Cancer 1987, 60, 433-436.
11. Naito H, Sasaki M, Yamashiro K, et al. Improvement in prognosis of neuroblastoma through mass population screening. J Pediatr Surg 1990, 25, 245-248.
12. Tuchman M., Lemieux B., Woods W. G. Screening for neuroblastoma in infants: Investigate or implement? Pediatrics. 86:1990;791-793.
13. Murphy SB, Cohn SL, Craft AW, et al. Do children benefit from mass screening for neuroblastoma? Consensus statement from the American Cancer Society Workshop on Neuroblastoma Screening. Lancet 1991, 337, 344-346.
14. Craft A. W., Parker L. Poor prognosis neuroblastoma: Is screening the answer? Br J Cancer. 66:1992;S96-S101.
15. Woods W. G. Screening for neuroblastoma in infants: More questions than answers. Screening. 1:1992;273-279.
16. Lemieux B, Auray-Blais C, Giguere R, et al. Quebec urinary screening program: 1. A service to the population. 2. A new perspective. In Therrell TL, ed. Advances in Neonatal Screening. Oxford, Elsevier Science Publishers, 1987, 209-210.
17. Tuchman M, Morris CL, Ramnaraine ML, et al. Value of random urinary homovanillic acid and vanillylmandelic acid levels in the diagnosis and management of patients with neuroblastoma: Comparison with 24 hour urine collections. Pediatrics 1985, 75, 324-328.
18. Lemieux B, Auray-Blais C, Campion P, Giguere R. Thin layer chromatography of homovanillic and vanillylmandelic acids applicable to a large scale neuroblastoma screening program. In Schmidt BJ, et al., eds. Current Trends in Infant Screening. Excerpta Medica, International Congress Series 848, 1989, 401-405.
19. Auray-Blais C., Giguere R., Lemieux B. Thin layer chromatography of urinary homovanillic acid and vanillylmandelic acid for large scale neuroblastoma mass screening. Med Pediatr Oncol. 17:1989;364-367.
20. Scriver CR, Gregory D, Bernstein ML, et al. Chemical screening of urine for neuroblastoma case finding in newborns: a feasibility study in Quebec. Can Med Assoc 1987, 136, 952-956.
21. Tuchman M, Lemieux B, Auray-Blais C, et al. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project. Pediatrics 1990, 86, 765-773.
22. Woods WG, Tuchman M, Bernstein M, et al. Screening for neuroblastoma in North America: two year results from the Quebec Project. Am J Pediatr Hematol Oncol 1992, 14, 312-319.
23. Lemieux B, Tuchman M, Leclerc JM, et al. The Quebec Neuroblastoma Screening Program: an update. In Sawada T, Matsumura T, Kizaki Z, eds. 3rd International Symposium on Neuroblastoma Screening. Kyoto, Japan, Kyoto Foundation for the Promotion of Medical Science, 1994, 75-84.
24. Campion P., Dupuis D. L. Neuroblastoma screening. The Canadian Nurse. 87:1991;17-19.
25. Tuchman M., Crippin P. J., Krivit W. Capillary gas chromatographic determinations of urinary homovanillic acid and vanillylmandelic acid. Clin Chem. 29:1983;828-831.
26. Evans A. E., D'Angio G. J., Randolph J. A proposed staging for children with neuroblastoma. Cancer. 27:1971;374-378.
27. Hayes FA, Green AA, Hustu HO, et al. Surgical pathologic staging of neuroblastoma: prognostic significance of regional lymph node metastases. J Pediatr 1983, 102, 59-62.
28. Brodeur GM, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 1988, 6, 1874-1881.
29. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993, 11, 1466-1477.
30. Bender A., MacDonald K. L. The Minnesota Cancer Surveillance System: a summary of 1988 data. Minn Dept Health Disease Control Newsletter. 19:1991;33-39.
31. Greenberg MC, Greenberg C. The Report of the Provincial Pediatric Oncology Working Group. Ontario Ministry of Health Publication, Toronto, 1994.
32. Kramer S., Meadows A. T., Jarrett P., Evans A. E. Incidence of childhood cancer: Experience of a decade in a population-based registry. J Natl Cancer Inst. 70:1983;49-55.
33. Miller BA, Ries LAG, Hankey BF, et al. SEER Cancer Statistics review: 1973-1990. Bethesda, Maryland, National Cancer Institute, NIH Publication No. 93-2789, 1993.
34. Gurney J. C., Severson R. K., Davis S., Robison L. L. Incidence of cancer in children in the United States: sex, race and 1-year age-specific rates by histologic type. Cancer. 75:1995;2186-2195.
35. Evans A. E., Baum E., Chard R. Do infants with stage IV-S neuroblastoma need treatment? Arch Dis Child. 56:1981;271-274.
36. Matthay KK, Sather HN, Seeger RC, et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989, 7, 236-244.
37. Kinnier-Wilson L. M., Draper G. J. Neuroblastoma, its natural history and prognosis: a study of 487 cases. Br Med J. 3:1974;301-307.
38. Pinkerton C. R. Where next with therapy in advanced neuroblastoma? Br J Cancer. 61:1990;351-353.
39. Philip T, Zucker JM, Bernard JL, et al. Improved survival at 2 and 5 years in the LMCE-1 unselected group of 72 children with stage 4 neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol 1991, 9, 1037-1044.
40. Laug WE, Siegel SE, Shaw KNF, et al. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978, 62, 77-83.
41. Tuchman M, Ramnaraine ML, Woods WG, et al. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Pediatrics 1987, 79, 203-205.
42. Pritchard J, Barnes J, Germond S, et al. Stage and urinary catecholamine metabolite excretion in neuroblastoma. Lancet 1989, 2, 514-515.
43. Woods W. G., Lemieux B., Tuchman M. Neuroblastoma represents distinct clinical-biologic entities: A review and perspective from the Quebec Neuroblastoma Screening Project. Pediatrics. 89:1992;114-118.
44. Bessho F., Hashizume K., Nakajo T., Kamoshita S. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr. 119:1991;237-241.
45. Yamamoto K, Hayashi Y, Hanada R, et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 1995, 13, 2033-2038.
46. Hayashi Y, Inaba T, Hanada R, et al. Similar chromosomal patterns and lack of N-myc gene amplification in localized and 4S stage neuroblastomas in infants. Med Pediatr Oncol 1989, 17, 111-115.
47. Ishimoto K, Kiyokawa N, Fujita H, et al. Problems of mass screening for neuroblastoma: analysis of false negative cases. J Pediatr Surg 1990, 25, 398-401.
48. Kaneko Y, Kanda N, Maseki N, et al. Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high risk neuroblastomas: a chromosome and N-myc amplification study. J Clin Oncol 1990, 8, 2005-2013.
49. Brodeur G. M., Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol-Oncol. 14:1992;111-116.
50. D'Angio G. J., Evans A. E., Koop C. E. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet. 1:1971;1046-1049.
51. Carlsen N. L. T. Epidemiological investigations on neuroblastomas in Denmark 1943-1980. Br J Cancer. 54:1986;977-988.
52. Draper GJ, Kroll ME, Stiller CA. Childhood cancer. In Cancer Surveys vol. 19/20: Trends in Cancer Incidence and Mortality. Imperial Cancer Research Fund, 1994, 493-517.
53. Parker L. SENSE: Study for the Evaluation of Neuroblastoma Screening in Europe. Abstracts from the Fourth International Symposium on Neuroblastoma Screening, Olgahospital, Stuttgart, 1995, 32.
54. Kushner BH, LaQuaglia MP, Ambros PF, et al. Survival from locally invasive or metastatic neuroblastoma (NB) without cytotoxic therapy (RX). Proc Am Soc Clin Oncol 1993, 12, 413.
55. Brodeur GM, Hayes FA, Green AA, et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from 60 individual patients. Cancer Res 1987, 47, 4248-4253.